Press Releases TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Delayed Nasdaq Other stock markets 12:48:18 14/05/2024 am IST			5-day change	1st Jan Change
1.85 ^USD	-5.13%		-14.35%	-73.65%

30/04	TFF Pharmaceuticals Prices $4.8 Million Public Offering; Shares Down Pre-Bell	MT
29/04	TFF Pharmaceuticals, Inc. Makes Available Phase 2 Data from Tacrolimus Inhalation Powder for Prevention of Lung Transplant Rejection Presented at Recent ISHLT Annual Meeting	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering	30/04	AQ
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting	29/04	AQ
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions	16/04	AQ
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions	15/04	AQ
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	29/03	AQ
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs	28/03	AQ
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting	25/03	AQ
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	20/03	AQ
TFF Pharmaceuticals Announces Update on Clinical Programs	20/03	AQ
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024	15/03	AQ
TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference	24/01	AQ
TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting	09/01	AQ
TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC	19/12	AQ
TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC	19/12	AQ
TFF Pharmaceuticals Announces Reverse Stock Split	15/12	AQ
TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors	13/12	AQ
TFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directors	30/11	AQ
TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors	30/11	AQ
TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023	27/11	AQ
TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update	15/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases TFF Pharmaceuticals, Inc.

Equities

TFFP

US87241J2033

Press Releases

Filters